Inside story: How Chinese biopharma firm WuXi will target European market from its €1 billion Dundalk campus

In what marks a first major foreign direct investment by a Chinese multinational in this country, WuXi has built one of the largest biopharma campuses in the world where it plans to produce 50 million vaccine doses a year – the Business Post

WuXi’s €325 million biologics manufacturing facility in Dundalk will commence commercial operations from the middle of next year